EUVIMEDScopri EUVIMED
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen access · CC BY 4.0

Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial

Joaquim J Ferreira, Olivier Rascol, Fabrizio Stocchi iD, Angelo Antonini, Joana Moreira, Guillermo Castilla-Fernández, José-Francisco Rocha iD, Joerg Holenz, Werner Poewe, Epsilon Study investigators

European Journal of Neurology · 2025

DOI: 10.1111/ene.16420 ↗

At a glance

Klinische Studie (Phase III) in European Journal of Neurology, 2025. Written by Joaquim J Ferreira and 9 co-authors. Institution: IMM - Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade Lisboa, Lisbon, Portugal. Major MEDLINE topics: Antiparkinson Agents, Drug Therapy, Combination, Levodopa, Parkinson Disease. Cited 10 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Catechol‐O‐methyl transferase (COMT) inhibitors are routinely used to manage motor fluctuations in Parkinson's disease (PD). We assessed the effect of opicapone on motor symptom severity in levodopa‐treated patients without motor complications.

Methods

This was a randomized, double‐blind, 24‐week, placebo‐controlled study of opicapone 50 mg as adjunct to levodopa (NCT04978597). Levodopa‐treated patients without motor complications were randomized to 24 weeks of double‐blind treatment with adjunct opicapone 50 mg or matching placebo. The primary efficacy endpoint was the mean change from baseline to week 24 in Movement Disorder Society‐Unified Parkinson's Disease Rating Scale Part III (MDS‐UPDRS‐III) total score.

Results

A total of 355 patients were randomized (opicapone 50 mg n = 177, placebo n = 178) and 322 (91%) completed the double‐blind period. The adjusted mean [95% CI] change from baseline to week 24 in MDS‐UPDRS‐III subscore was −6.5 [−7.9, −5.2] in the opicapone group versus −4.3 [−5.7, 3.0] in the placebo group resulting in a significant difference of −2.2 [−3.9, −0.5] favoring opicapone ( p = 0.010). There was no difference in the incidence of patients who developed motor complications (5.5% with opicapone vs. 9.8% with placebo) and the incidence of adverse events considered related to study medication was similar between groups (opicapone 10.2% vs. placebo 13.5%).

Conclusions

Treatment with once‐daily adjunct opicapone was well tolerated, improved motor severity, and did not induce the development of motor complications. These results support the clinical usefulness of opicapone in the management of PD patients without motor complications.

Subjects

MeSH terms (MEDLINE)

Antiparkinson AgentsDrug Therapy, CombinationLevodopaParkinson DiseaseAgedFemaleHumansMaleMiddle AgedCatechol O-Methyltransferase InhibitorsDouble-Blind MethodOxadiazolesSeverity of Illness IndexTreatment Outcome

Author keywords

COMTParkinson's diseaseclinical triallevodopaopicapone

Substances

Antiparkinson AgentsCatechol O-Methyltransferase InhibitorsLevodopaopicaponeOxadiazoles

Authors and institutions

  • IMM - Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade Lisboa, Lisbon, Portugal.
  • CNS - Campus Neurológico, Torres Vedras, Portugal.
  • Clinical Investigation Centre CIC1436, Department of Neurosciences and Clinical Pharmacology, Centre of Excellence for Neurodegeneration COEN NeuroToul, and NS-Park/FCRIN Network, University of Toulouse 3, University Ho…
  • University San Raffaele Roma and Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy.
  • Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Padua, Italy.
  • BIAL - Portela & Ca S.A, Coronado, Portugal.

ORCID profiles: Fabrizio Stocchi, José-Francisco Rocha

Cite

APA

Ferreira, J. J., Rascol, O., Stocchi, F., Antonini, A., Moreira, J., Castilla-Fernández, G., Rocha, J. F., Holenz, J., Poewe, W., & Epsilon Study investigators (2025). Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial. European Journal of Neurology. https://doi.org/10.1111/ene.16420

Vancouver

Ferreira JJ, Rascol O, Stocchi F, Antonini A, Moreira J, Castilla-Fernández G, et al. Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial. European Journal of Neurology. 2025. doi:10.1111/ene.16420

BibTeX
@article{Ferreira2025,
  author = {Ferreira, Joaquim J and Rascol, Olivier and Stocchi, Fabrizio and Antonini, Angelo and Moreira, Joana and Castilla-Fernández, Guillermo and Rocha, José-Francisco and Holenz, Joerg and Poewe, Werner and Epsilon Study investigators, Epsilon Study investigators},
  title = {Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.16420}
}
Start for free →